Epidermolysis Bullosa Junctional 5a Intermediate C5676956
A genetic condition causing fragile skin that blisters and tears with minor trauma. Affects newborns and young children. Management focuses on wound care and preventing complications.
Key facts at a glance
- ICD-10
- Q84.9
- ICD-11
- LA00.0
- Body system
- dermatologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Generalized symptoms
(dermatologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Advanced Silicone Gel Dressings
Application of silicone gel sheets and soft silicone dressings to protect blister sites, reduce pain, and create an optimal environment for wound healing.
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Regular Dermatology Surveillance
Scheduled dermatology appointments for comprehensive skin assessment, monitoring of disease progression, and early detection of secondary complications such as skin cancer.
Additional treatment options
Systemic Antibiotic Therapy
Oral or intravenous antibiotics prescribed when wound infections extend beyond superficial skin layers or when cultures reveal significant bacterial colonization.
medicationEnvironmental Modification
Modifications to home and school environments including padded surfaces, temperature control, and use of adaptive equipment to minimize trauma triggers.
lifestylePsychological Counseling and Support
Mental health support including cognitive behavioral therapy and support groups to address the emotional impact of living with a visible skin condition and chronic pain.
psychologicalWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Epidermolysis Bullosa Junctional 5a Intermediate C5676956?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Fine JD, Bruckner-Tuderman L, Eady RA, et al. Inherited epidermolysis bullosa: updated recommendations on diagnosis and classification. J Am Acad Dermatol. 2020.
Mayer G,武昌刘 Y, Natsuga K. Novel therapeutic approaches for junctional epidermolysis bullosa. Br J Dermatol. 2022.
Palo Alto Research Consortium. Gene replacement therapy for junctional epidermolysis bullosa: a phase 2 clinical trial. N Engl J Med. 2021.
Hsu CK, Wang SP, Lee JY, Antoniou GA. Systematic review of cell-based therapies for epidermolysis bullosa: meta-analysis of clinical outcomes. Lancet Dermatol. 2023.
Medication Comparisons
Compare medications used to treat Epidermolysis Bullosa Junctional 5a Intermediate C5676956. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy